17:21 , Aug 30, 2018 |  BC Innovations  |  Tools & Techniques

Master of autism

The discovery of a master regulator of autism risk genes has yielded the first mouse model of the form of the condition that accounts for about 90% of patients, and could spark a new way...
19:34 , May 17, 2018 |  BC Innovations  |  Finance

Europe’s piece of the pie

With China’s rising infrastructure for life science innovation and the unabated growth of U.S. science, Europe has two cards to play that can help it compete globally: expertise in key core technologies and its centralized...
20:27 , Nov 16, 2017 |  BC Innovations  |  Translation in Brief

Lighting up the DYRK

Kyoto University researchers have described a DYRK1A inhibitor that could treat neuronal deficits in Down syndrome with fewer side effects than other inhibitors of the kinase -- but neurology company NeuroNascent Inc. suggests the safety...
19:22 , Sep 19, 2017 |  BC Innovations  |  Distillery Therapeutics

Neurology

INDICATION: Cognitive dysfunction In vitro and mouse studies identified an indazole-based inhibitor of DYRK1A that could help treat Down syndrome in fetuses. Screening of a small molecule library in mouse neural stem cells identified a...
08:00 , Jan 7, 2016 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Dual-specificity tyrosine-(Y)-phosphorylation regulated kinase 1A (DYRK1A); glycogen synthase kinase 3β (GSK3β)

Endocrine/metabolic disease INDICATION: Diabetes In vitro, rodent and human tissue studies suggest dual inhibitors of GSK3β and DYRK1A could increase β cell mass to help treat diabetes. Chemical synthesis of aminopyrazine analogs and testing in...
07:00 , Jul 20, 2015 |  BioCentury  |  Emerging Company Profile

Shot in the DYRK

Felicitex Therapeutics Inc. is discovering and developing small molecule cancer agents that target cell quiescence, a mechanism cancer cells can use to resist treatment. Cell quiescence is a reversible phenomenon where cells stop dividing and...
07:00 , Mar 26, 2015 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Dual-specificity tyrosine-(Y)-phosphorylation regulated kinase 1A (DYRK1A)

Endocrine/metabolic disease INDICATION: Diabetes In vitro and mouse studies suggest DYRK1A inhibitors could help treat diabetes. In human islets and rat β cells, the DYRK1A inhibitor harmine or shRNA targeting DYRK1A increased proliferation compared with...
07:00 , May 12, 2014 |  BioCentury  |  Emerging Company Profile

Pharmasum: Down with AD

Pharmasum Therapeutics A/S is looking to treat the large number of Down syndrome patients who develop Alzheimer's disease-like pathology. The company's first-in-class inhibitor could slow cognitive decline in Down syndrome by targeting a kinase that...
07:00 , Apr 21, 2014 |  BC Week In Review  |  Company News

Lytix, Pharmasum Therapeutics neurology news

Infectious disease and cancer company Lytix spun out Pharmasum to develop PST-900 , a dual-specificity tyrosine-(Y)-phosphorylation regulated kinase 1A (DYRK1A) inhibitor to treat dementia. Pharmasum hopes to move the discovery-stage compound into the clinic in...
07:00 , May 16, 2013 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Brain cancer Dual-specificity tyrosine-(Y)-phosphorylation-regulated kinase 1A (DYRK1A); epidermal growth factor receptor (EGFR) Cell culture and mouse studies suggest inhibiting DYRK1A could...